CCL

Összesen 14 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM038652
Első szerző:Alberth Márta (fogszakorvos)
Cím:Significance of oral Candida infections in children with cancer / Alberth M., Majoros L., Kovalecz G., Borbás E., Szegedi I., Márton I. J., Kiss C.
Dátum:2006
ISSN:1219-4956
Megjegyzések:Candidiasis is common in children with cancer, particularly during periods of severe immunosuppression and neutropenia. Our aim was to study the microbiological changes in the oral cavity of children with newly diagnosed cancer. The study group consisted of 30 consecutive children and adolescents, 16 with acute lymphoblastic leukemia and 14 with solid tumors. Oral cultures to detect fungi and bacteria were conducted for all patients before treatment, during and after neutropenic episodes. In 23 patients developing fever simultaneous throat, urine and blood sampling was carried out. No pathogens were found in the cultures taken before the outset (30 cultures) or after recovery from (30 cultures) the neutropenic episodes. In the 45 oral cultures taken during the neutropenic episodes 38 (84.4%) proved positive. Fungi were the most frequently isolated oral pathogens: 33/38 yeast and 6/38 bacterial infections were identified. There was no association between the underlying malignancy and the occurrence of the positive cultures. Of the 30 patients, all 23 (76.7%) who have developed moderate-to-severe neutropenia, developed oral fungal colonization or clinically obvious fungal infection at least on one occasion during the study. In addition to oral samples, fungi were identified in 9/23 pharyngeal swabs, 6/23 urine and 1/23 blood cultures. The initial fungal pathogen was exclusively (33/33) Candida albicans. In extended severe neutropenic states, C. albicans was replaced by non-albicans species (C. kefyr, C. lusitaniae, C. sake, C. tropicalis) in 5 patients between 4 to 6 days of the neutropenic episodes. Four of the nonalbicans Candida strains were resistant to azole-type antifungal agents. Neutropenic episodes of children with cancer are associated with an increased risk of developing oral and even systemic infections with C. albicans that can be replaced by azole-resistant nonalbicans strains in prolonged neutropenia contributing to morbidity of these patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Pathology and Oncology Research. - 12 : 4 (2006), p. 237-241. -
További szerzők:Majoros László (1966-) (szakorvos, klinikai mikrobiológus) Kovalecz Gabriella (1973-) (fogszakorvos) Borbás Emese Szegedi István (1969-) (hematológus, onkológus, nefrológus) Márton Ildikó (1954-) (fogszakorvos) Kiss Csongor (1956-) (hematológus, onkológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM049348
035-os BibID:(PMID)23955198 (Scopus)84896034980 (WOS)000329356600017
Első szerző:Bárdi Edit (csecsemő- és gyermekgyógyász)
Cím:Value of FDG-PET/CT Examinations in Different Cancers of Children, Focusing on Lymphomas / Edit Bárdi, Mónika Csóka, Ildikó Garai, István Szegedi, Judit Müller, Tamás Györke, Kornélia Kajáry, Karolina Nemes, Csongor Kiss, Gábor Kovács
Dátum:2014
ISSN:1219-4956 1532-2807
Megjegyzések:The aim of the study was to assess sensitivity and specificity of FDG-PET/CT in different forms of childhood cancer. We retrospectively evaluated the results dedicated of 162 FDG-PET/CT examinations of 86 children treated with: Hodgkin lymphoma (HL; n=31), non-Hodgkin lymphoma (NHL; n=30) and other high grade solid tumors (n=25). Patients were admitted and treated in two departments of pediatric hematology and oncology in Hungary. FDG-PET/CT was performed for staging (n=25) and for posttreatment evaluation (n=137). Imaging was performed in three FDG-PET/CT Laboratories, using dedicated PET/CT scanners. False positive results were defined as resolution or absence of disease progression over at least 1 year on FDG-PET/CT scans without any intervention. In some cases histopathological evaluation of suspicious lesions was performed. Fals negative results were defined as negative FDG-PET/CT results in case of active malignancy. Positive predictive values (PPV) and negative predictive values (NPV) were calculated. NPV was 100 %. The highest PPV was observed in high grade solid tumors (81 %), followed by HL (65 %) and NHL (61 %). There was a major difference of PPV in different histological types of HL (50 % in HL of mixed-cellularity subtype, 90 % in nodular sclerosing, and 100 % in lymphocyte-rich and lymphocyte depleted HL). We treated one patient with nodular lymphocyte predominant HL, who had 5 false positive FDG-PET/CT results. PPV of T- and B-lineage NHL were similar (60 % and 62 %, respectively). We observed an interesting difference of PPV in different stages of HL and NHL. In HL PPV was higher in early than in advanced disease forms: 66 % in stage II HL and 60 % in stage III HL, whereas there was an inverse relationship between PPV and disease stages in NHL 0 % in stage I and II patients, 67 % in stage III and 100 % in stage IV patients. PPV was lower in males (54 %) than in females (65 %). PPV were 64 % vs. 58 % in patients under vs. over 10 years of age. Negative FDG-PET/CT results during follow-up reliably predict the absence of malignancy. Positive FDG-PET/CT scan results in general have a low PPV. The relatively high PPV in patients with histologically proven high grade solid tumors, advanced stages of NHL and with nodular sclerosing, lymphocyte-rich and lymphocyte depleted subtypes of HL warrant a confirmation by biopsy, whereas the watch-and-wait approach can be used in other forms of childhood cancer patients with a positive FDG-PET/CT result in course of follow-up examinations.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
FDG-PET/CT
Megjelenés:Pathology Oncology Research. - 20 : 1 (2014), p. 139-143. -
További szerzők:Csóka Mónika Garai Ildikó (1966-) (radiológus) Szegedi István (1969-) (hematológus, onkológus, nefrológus) Müller Judit Györke Tamás Kajáry Kornélia Nemes Karolina Kiss Csongor (1956-) (hematológus, onkológus) Kovács Gábor (gyermekhaematológus Budapest)
Pályázati támogatás:TÁMOP-4.2.2.A-11/1/KONV-2012-0025
TÁMOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM011927
Első szerző:Bárdi Edit (csecsemő- és gyermekgyógyász)
Cím:Differential Effect of Corticosteroids on Serum Cystatin C in Thrombocytopenic Purpura and Leukemia / Bárdi E., Dobos E., Kappelmayer J., Kiss C.
Dátum:2010
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Pathology and Oncology Research. - 16 : 3 (2010), p. 453-456. -
További szerzők:Dobos Éva Kappelmayer János (1960-) (laboratóriumi szakorvos) Kiss Csongor (1956-) (hematológus, onkológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

4.

001-es BibID:BIBFORM001928
Első szerző:Bárdi Edit (csecsemő- és gyermekgyógyász)
Cím:Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer / Bárdi E., Bobok I., V. Oláh A., Kappelmayer J., Kiss C.
Dátum:2007
Megjegyzések:Experimental evidence suggests that anthracyclines, widely used in cancer chemotherapy, may impair kidney function. We assessed kidney function by serum creatinine, urinary N-acetyl-?-D-glucosaminidase activity indices (NAGi) and microalbuminuria (MA) in 160 serum and urine samples obtained from 66 children with cancer. The effect of dexrazoxane was analyzed in 6 children on dexrazoxane supportive therapy in conjunction with daunorubicin (DNR) treatment, as compared with 6 children notreceiving this agent. NAGi was significantly (p<0.05) elevated after treatment by DNR, doxorubicin, epirubicin (EPI) and idarubicin (IDA). MA proved to be a less sensitive indicator of kidney damage than NAGi. DNR resulted in a progressive deterioration of proximal tubular function as determined by linear regression analysis. The mean NAGi in the dexrazoxanetreated group was significantly (p<0.005) lower than in children not receiving dexrazoxane prior to DNR treatment. In conclusion, our study demonstrated that DNR, EPI and IDA induced an acute renal tubular damage similar to known tubulotoxic agents as cisplatin, carboplatin, cyclophosphamide and ifosfamide. The damage was clinically mild and only a minor proportion of patients can be expected to develop long-lasting tubulopathy with negative impact on the quality of life.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
nephrotoxicity
anthracycline therapy
dexrazoxane
NAGi
microalbuminuria
egyetemen (Magyarországon) készült közlemény
Megjelenés:Pathology and Oncology Research. - 13 : 3 (2007), p. 249-253. -
További szerzők:Bobok Ildikó Oláh Anna (1956-) (klinikai biokémikus, vegyész) Kappelmayer János (1960-) (laboratóriumi szakorvos) Kiss Csongor (1956-) (hematológus, onkológus)
Internet cím:elektronikus változat
Borító:

5.

001-es BibID:BIBFORM070453
035-os BibID:(WOS)000443977800015 (Scopus)85028751480
Első szerző:Horváth József (molekuláris genetikus)
Cím:Oral Health May Affect the Performance of mRNA-Based Saliva Biomarkers for Oral Squamous Cell Cancer / Horváth József, Szabó Adrienn, Tar Ildikó, Dezső Balázs, Kiss Csongor, Márton Ildikó, Scholtz Beáta
Dátum:2018
ISSN:1219-4956 1532-2807
Megjegyzések:Oral squamous cell carcinoma (OSCC) has a dismal 50% five-year survival rate, emphasizing the need to develop reliable and sensitive tools for early diagnosis. In this study we evaluated the performance of 7 previously identified, potential mRNA biomarkers of OSCC in saliva samples of Hungarian patients. Expression of the putative OSCC biomarkers (DUSP1, OAZ1, H3F3A, IL1B, IL8, SAT and S100P), 2 biomarkers of inflammation (IL6 and TNF) and 8 putative normalizing genes was quantified from each sample using real-time quantitative PCR. In contrast with previous studies, the expression pattern of the 7 mRNA biomarkers was similar between OSCC patients and age-matched control patients in the Hungarian patient population. On the other hand, 5 of the 7 mRNA biomarkers were present at significantly higher levels in saliva samples of OSCC patients when compared to young control patients. The best biomarker combination could distinguish only the OSCC vs. young control patients, but not the OSCC vs. age-matched control patients. In conclusion, the significant differences between our results and previous studies, and the clinical characteristics of the patients suggest that inflammatory processes in the oral cavity may affect the performance of the 7 putative salivary mRNA biomarkers. Lastly, since IL6 mRNA was quantifiable in the majority of OSCC cases, but only in a few control samples, salivary IL6 mRNA may be utilized as part of a biomarker combination to detect OSCC.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
saliva biomarkers
OSCC
SalivamRNA
Biomarker
Saliva based diagnostics
qPCR
Megjelenés:Pathology & Oncology Research. - 24 : 4 (2018), p. 833-842. -
További szerzők:Szabó Adrienn (1965-) (egyetemi tanársegéd, fogszakorvos) Tar Ildikó (1967-) (fogszakorvos) Dezső Balázs (1951-) (pathológus) Kiss Csongor (1956-) (hematológus, onkológus) Márton Ildikó (1954-) (fogszakorvos) Scholtz Beáta (1967-) (biokémikus, molekuláris biológus)
Pályázati támogatás:ID K 105034
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM040735
Első szerző:Jenei Zoltán (belgyógyász)
Cím:Anthracycline causes impaired vascular endothelial function and aortic stiffnes in long term survivors of childhood cancer / Zoltán Jenei, Edit Bárdi, Mária Tünde Magyar, Ágnes Horváth, György Paragh, Csongor Kiss
Dátum:2013
ISSN:1532-2807
Megjegyzések:Vascular and endothelial functions were investigated in long term survivors of childhood cancer exposed to anthracycline treatment. We enrolled 96 long-term survivors (57 males and 39 females, mean age 14.9±5.3 year) of different childhood cancers and 72 age-, sex-, bodyweight- and blood pressure matched controls (39 males and 33 females, mean age 13.7±4.9 year). Aortic stiffness was characterized by echocardiography. Brachial artery endothelial function was assessed by flow-mediated dilatation (FMD%) and nitrate-mediated dilatation (NTG%). Results were compared between three subgroups: anthracycline treated, only chemotherapy treated and control subgroups. The cumulative anthracycline dose was less than 350 mg/m(2). The healthy control subgroup had a significantly greater FMD response (13.13±2.40 %), and lower stiffness index (2.08±0.6) than both the anthracycline (7.12±6.28 % and 6.45±3.25, respectively) and only chemotherapy treated (10.17±4.23 % and 4.12±2.32, respectively) subgroups. In the anthracycline treated subgroup a significantly (p<0.01) lower FMD% response, and higher stiffness index were detected than in the only chemotherapy treated subgroup. Higher triglyceride level, higher cumulative anthracycline dose and lower age at the start of treatment were found to be associated independently with impairment of FMD% response and aortic stiffness. We found a significant negative correlation between FMD and aortic stiffness (p<0.001) and a positive correlation between FMD and distensibility (p<0.0001) Childhood cancer long term survivors exposed to anthracycline treatment exhibit a marked preclinical vasculopathy, characterized by endothelial dysfunction and increased arterial stiffness, contributing to a deteriorated cardiovascular function.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Egészség- és Környezettudomány
Megjelenés:Pathology & Oncology Research. - 19 : 3 (2013), p. 375-383. -
További szerzők:Bárdi Edit (1971-) (csecsemő- és gyermekgyógyász) Magyar Mária Tünde (1970-) (neurológus) Horváth Ágnes (1985-) (reumatológus) Paragh György (1953-) (belgyógyász) Kiss Csongor (1956-) (hematológus, onkológus)
Pályázati támogatás:ETT 396/2006
Egyéb
01-478/2009
Egyéb
TÁMOP-4.2.1/B-09/1/KONV-2010-0007
TÁMOP
Rosszindulatú daganatos megbetegedések serdülő és fiatal felnőttkorban
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Szerző által megadott URL
DOI
Borító:

7.

001-es BibID:BIBFORM069451
035-os BibID:(WOS)000427432400020 (Scopus)85019612221
Első szerző:Kárai Bettina (orvos)
Cím:Expression of Coagulation Factor XIII Subunit A Correlates with Outcome in Childhood Acute Lymphoblastic Leukemia / Bettina Kárai, Zsuzsanna Hevessy, Eszter Szánthó, László Csáthy, Anikó Ujfalusi, Katalin Gyurina, István Szegedi, János Kappelmayer, Csongor Kiss
Dátum:2018
ISSN:1219-4956 1532-2807
Megjegyzések:Abstract Previously we identified B-cell lineage leukemic lymphoblasts as a new expression site for subunit A of blood coagulation factor XIII (FXIII-A). On the basis of FXIII-A expression, various subgroups of B-cell precursor acute lymphoblasticleukemia (BCP-ALL) can be identified. Fifty-five children with BCP-ALL were included in the study. Bone marrow samples were obtained by aspiration and the presenceof FXIII-A was detected by flow cytometry. G-banding and fluorescent in situ hybridization was performed according to standard procedures. The 10-year event-free survival (EFS)and overall survival (OS) rate of FXIII-A-positive and FXIII-A-negative patients showed significant differences (EFS: 84% vs. 61%, respectively; p = 0.031; OS: 89% vs.61%; p = 0.008). Of all the parameters examined, there was correlation only between FXIII-A expression and ♭B-other' genetic subgroup. Further multivariate Cox regression analysis of FXIII-subtype and genetic group or ♭B-other' subgroup identified the FXIII-A negative characteristic as an independent factor associated with poor outcome in BCP-ALL. We found an excellent correlation between long-term survival and the FXIII-A-positive phenotype of BCP lymphoblasts at presentation. The results presented seem to be convincing enough to suggest a possible role for FXIII-A expression in the prognostic grouping of childhood BCP-ALL patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Precursor B-cell acute lymphoblastic leukemia
Immunophenotype
Factor XIII-A
B-other' ALL
Megjelenés:Pathology and Oncology Research. - 24 : 2 (2018), p. 345-352. -
További szerzők:Hevessy Zsuzsanna (1966-) (laboratóriumi szakorvos) Szánthó Eszter (laboratóriumi szakorvos jelölt) Csáthy László (1979-) (laboratóriumi szakorvos) Ujfalusi Anikó (1968-) (gyermekorvos, laboratóriumi szakorvos) Gyurina Katalin (1986-) (tudományos segédmunkatárs) Szegedi István (1969-) (hematológus, onkológus, nefrológus) Kappelmayer János (1960-) (laboratóriumi szakorvos) Kiss Csongor (1956-) (hematológus, onkológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM102344
035-os BibID:(cikkazonosító)1610171 (WOS)000814739700001 (Scopus)85132960654
Első szerző:Kertész Gabriella
Cím:Case Report : a Child With Hemophilia A Serves as Donor for Hematopoietic Stem Cell Transplantation to Cure His Brother's Severe Aplastic Anemia / Kertész Gabriella, Kállay Krisztián, Kassa Csaba, Zombori Marianna, Bodó Imre, Kiss Csongor, Szegedi István, Kriván Gergely
Dátum:2022
ISSN:1219-4956 1532-2807
Megjegyzések:The first-line treatment of severe aplastic anemia is allogeneic hematopoietic stem cell transplantation with a matched sibling donor. However, co-morbidities of the identical donor can make donation difficult. We present a transplantation where in parallel with the patient's conditioning treatment, the preparation of the donor with severe hemophilia A required a special management with perioperative factor VIII substitution. Donation was successful without complications, and 18 months after transplantation, the patient and his donor are well without any long-term sequelae. To our knowledge, this is the first reported succesfull transplantation with hemophilic child serving as a bone marrow donor. The procedure did not mean a significant risk to donor health, so donors with hemophilia should not be excluded from donation.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Pathology & Oncology Research. - 28 (2022), p. 1-5. -
További szerzők:Kállay Krisztián Kassa Csaba Zombori Marianna Bodó Imre Kiss Csongor (1956-) (hematológus, onkológus) Szegedi István (1969-) (hematológus, onkológus, nefrológus) Kriván Gergely
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM044544
Első szerző:Mikala Gábor
Cím:Human herpesvirus 8 in hematologic diseases / Gábor Mikala, Jiuru Xie, György Berencsi, Csongor Kiss, Ildikó Márton, Gyula Domján, István Vályi-Nagy
Dátum:1999
ISSN:1219-4956 1532-2807
Megjegyzések:Human herpesvirus type 8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV) is a new member of the g-herpesvirus family. It is an unusual herpesvirus in that it carries a large number of genes that encode oncoproteins or cell signaling proteins. In addition to being the causative agent of both HIV-associated and non-HIV-associated Kaposi's sarcoma this DNA tumor virus has been implicated in the pathogenesis of several diseases. These include multiple myeloma (MM), Waldenstöm's macroglobulinemia (WM), multicentric Castleman's disease (MCD), body cavity-based lymphoma (BCBL), and various other conditions such as sarcoidosis and pemphigus. While the causative role of the viral infection is fairly certain in the development of BCBL and multicentric Castleman's disease, HHV-8 may act through a different mechanism to induce plasma cell malignancies. It has been suggested though the finding is still controversial - that infection of bone marrow stromal dendritic cells by HHV-8 might be a key factor in the etiology and pathogenesis of monoclonal gammopathies. The aim of this review is to provide a short introduction into the tumorigenic potential of HHV-8 as well as to detail the available data and possible mechanisms on the involvement of this virus in different hematologic diseases.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Pathology & Oncology Research. - 5 : 1 (1999), p. 73-79. -
További szerzők:Xie, Jiuru Berencsi György Kiss Csongor (1956-) (hematológus, onkológus) Márton Ildikó (1954-) (fogszakorvos) Domján Gyula Vályi-Nagy István
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM101209
035-os BibID:(cikkazonosító)1610261 (WOS)000784109200001 (Scopus)85128409153
Első szerző:Müller Judit
Cím:Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary / Müller Judit, Szűcs-Farkas Dóra, Szegedi István, Csóka Monika, Garami Miklós, Tiszlavicz Lilla Györgyi, Hauser Péter, Kriván Gergely, Csanádi Krisztina, Ottóffy Gábor, Nagy Béla, Kiss Csongor, Kovács Gábor
Dátum:2022
ISSN:1219-4956 1532-2807
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
SARS-CoV-2
COVID-19
pediatric malignancy
chemotherapy delay
SARS-CoV-2S antibodies
Megjelenés:Pathology & Oncology Research. - 28 (2022), p. 1-6. -
További szerzők:Szűcs-Farkas Dóra Szegedi István (1969-) (hematológus, onkológus, nefrológus) Csóka Mónika Garami Miklós Tiszlavicz Lilla Györgyi Hauser Péter Kriván Gergely Csanádi Krisztina Ottóffy Gábor Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos) Kiss Csongor (1956-) (hematológus, onkológus) Kovács Gábor (gyermekhaematológus Budapest)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM003788
Első szerző:Nemes Judit (fogszakorvos)
Cím:Oral cancer report from Northeastern Hungary / Judit A. Nemes, Pál Redl, Róbert Boda, Csongor Kiss, Ildikó J. Márton
Dátum:2008
Megjegyzések:In Hungary oral and pharyngeal cancers have been reported the fourth most common malignancy in males and the sixth for both sexes. The aim of the present study was to characterize oral squamous cell carcinoma(OSCC) patients in Northeastern Hungary. 119 randomly selected patients with OSCC were included in the study. Epidemiological data, clinicopathological parameters and the risk factors were registered. The most common sites of OSCC were the floor of the mouth (27.7%), the lip (26.9%) and the tongue (22.7%). The majority of the patients was diagnosed with early stage (I?II) lesions and moderately differentiated tumors. The 5-year overall survival rate was 38.7%. There was a significant correlation between survival and tumor size, lymph node involvement and clinical stage. At the time of diagnosis 65.5% of the patients were smokers. Smoking significantly correlated with younger age, male gender, advanced clinical stages and alcohol consumption. 75.5% of the patients consumed alcohol, 41.1% of them exceeding the conventional amount regularly. Drinking habit significantly correlated with younger age, male gender and tumor site i.e. gingiva, retromolar region, tongue. The dental status was acceptable only in 12.6% of the cases. There was a significant correlation between dental status and age, smoking and drinking habits. Clinical stage has the most significant impact on survival and the most important high-risk habits in Northeastern Hungary are smoking and alcohol consumption. Therefore, early detection and treatment, cessation of tobacco and alcohol abuse, and a regular dental care may improve patients' survival in the region.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
oral cancer
squamous cell carcinoma
survival
Northeastern Hungary
Megjelenés:Pathology and Oncology Research. - 14 (2008), p. 85-92. -
További szerzők:Redl Pál (1953-) (szájsebész) Boda Róbert (1978-) (fogszakorvos) Kiss Csongor (1956-) (hematológus, onkológus) Márton Ildikó (1954-) (fogszakorvos)
Internet cím:elektronikus változat
DOI
Borító:

12.

001-es BibID:BIBFORM002279
Első szerző:Rényi Imre (gyermekhaematológus Budapest)
Cím:Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and Non-Hodgkin's lymphoma / Rényi Imre, Bárdi Edit, Udvardy Erzsébet, Kovács Gábor, Bartyik Katalin, Kajtár Pál, Masát Péter, Nagy Kálmán, Galántai Ilona, Kiss Csongor
Dátum:2007
Megjegyzések:To prevent acute renal failure in children at risk for developing tumor lysis syndrome due to acute lymphoblastic leukemia or non-Hodgkin's lymphoma treated according to international BFM protocols, we investigated recombinant urate oxidase (rasburicase) in the first Central European openlabeled, prospective, multicenter phase IV trial. Rasburicase was administered intravenously, at 0.2 mg/kg for 5 consecutive days to 36 patients. Blood levels of uric acid, creatinine, phosphorus, calcium lactate dehydrogenase and complete blood count were measured daily during rasburicase treatment and on days 6, 7 and 12. Initial uric acid level decreased significantly by 4 hours (from 343 gamma mol/L to 58 gamma mol/L, p<0.001), except for one steroid-resistant patient who required hemodialysis on day 14 after having introduced combined cytostatic treatment. Comparing the data of a subgroup of 12 patients receiving rasburicase with that of a historic cohort of 14 patients treated with allopurinol indicated the superiority of rasburicase over allopurinol in prophylaxis and treatment of hyperuricemia in children with leukemia and lymphoma.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
rasburicase
uric acid
tumor lysis syndrome
leukemia
lymphoma
Megjelenés:Pathology and Oncology Research 13 : 1 (2007), p. 57-62. -
További szerzők:Bárdi Edit (1971-) (csecsemő- és gyermekgyógyász) Udvardy Erzsébet Kovács Gábor Bartyik Katalin (haematológus) Kajtár Pál Masát Péter (gyermekorvos Szombathely) Nagy Kálmán Galántai Ilona (onkológus Budapest) Kiss Csongor (1956-) (hematológus, onkológus)
Internet cím:elektronikus változat
elektronikus változat
Borító:
Rekordok letöltése1 2 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.